AML therapy
NPM1-mutated AML
specific AML genetic context
landscape of AML genomics
deciphering AML molecular subsets
specific therapy
new therapeutic approaches
new targets
new discoveries
mutated acute myeloid leukemia Acute myeloid leukemia
new entity
therapeutic targets
novel therapeutic approaches
clinical heterogeneity
screening-based approach
complex network of molecular interactions
clinical trials available
classification of myeloid neoplasms
distinct genetic subtype
frequent genetic alteration
CRISPR-based genome-wide interference
role of specific intracellular pathways
genome sequencing
characterized nucleophosmin
relevant pre-clinical models
synthetic lethal interactions
recurrent somatic mutations
hypothesis-driven approach
adult young patients
recent gained novel insights
place
pharmacological studies
high-throughput chemical libraries screenings
laboratories
vulnerabilities
advantage
advances
concurrent improvements
group of hematologic malignancies
complementary strategies
drugs
mechanisms of leukemogenesis
past years
antracycline
cytarabine
scheme
generation
elderly
disease
issue